Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10901a3ef1d1f073204ef5455fa640a4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6807 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2019-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb7e25d49adcdfab77ba5299f8664a6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb4d28928e95eee49f1b52b62e02e81b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61b101cd8a28a5d7e2acb246adeb9907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_608e8c15dfc57cc655368bbc4333afad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6854dd05188282c422bace38c865de87 |
publicationDate |
2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020081744-A1 |
titleOfInvention |
Immunomodulating polynucleotide conjugates and methods of use |
abstract |
Provided herein is a conjugate for modulating a natural killer cell or myeloid cell, comprising a targeting moiety and an immunomodulating polynucleotide. Also provided herein is a pharmaceutical composition for modulating a natural killer cell or myeloid cell, comprising a conjugate comprising a targeting moiety and an immunomodulating polynucleotide, and a pharmaceutically acceptable excipient. Additionally provided herein are methods of their use for modulating a natural killer cell or myeloid cell and treating a proliferative disease. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023081934-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023023659-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023028511-A1 |
priorityDate |
2018-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |